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Abstract Patients with non-transfusion-dependent thalasse-
mia (NTDT) often develop iron overload that requires che-
lation to levels below the threshold associated with compli-
cations. This can take several years in patients with high iron
burden, highlighting the value of long-term chelation data.
Here, we report the 1-year extension of the THALASSA trial
assessing deferasirox in NTDT; patients continued with
deferasirox or crossed from placebo to deferasirox. Of 133
patients entering extension, 130 completed. Liver iron con-
centration (LIC) continued to decrease with deferasirox over
2 years; mean change was −7.14 mg Fe/g dry weight (dw)
(mean dose 9.8±3.6 mg/kg/day). In patients originally ran-
domized to placebo, whose LIC had increased by the end of
the core study, LIC decreased in the extension with defera-
sirox with a mean change of −6.66 mg Fe/g dw (baseline to
month 24; mean dose in extension 13.7±4.6 mg/kg/day). Of
166 patients enrolled, 64 (38.6 %) and 24 (14.5 %) patients
achieved LIC <5 and <3 mg Fe/g dw by the end of the study,
respectively. Mean LIC reduction was greatest in patients
with the highest pretreatment LIC. Deferasirox progressively
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decreases iron overload over 2 years in NTDT patients with
both low and high LIC. Safety profile of deferasirox over
2 years was consistent with that in the core study.
Keywords Iron overload . Iron chelation . Non-transfusion-
dependent thalassemia . Deferasirox
Introduction
In patients with non-transfusion-dependent thalassemias (NTDT),
such as beta-thalassemia intermedia, alpha-thalassemia (mainly
HbH disease), and mild/moderate forms of HbE/beta-thal-
assemia, iron overload is an important challenge in terms
of diagnosis, monitoring, and treatment. Increased intesti-
nal absorption of iron, caused by ineffective erythropoie-
sis, is the main cause of iron overload in these patients,
which can become clinically relevant by the age of 10
years [1]. Iron overload is associated with liver dysfunc-
tion and vascular, bone, and endocrine morbidities [2]. A
wealth of information on iron overload and its manage-
ment is available from transfusion-dependent beta-
thalassemia major. However, given the differences in iron
metabolism, pathophysiology, and iron loading rate in
patients with NTDT, a direct extrapolation cannot be
made, making it important to investigate iron overload
in NTDT [3–11].
THALASSA (assessment of Exjade® in non-transfusion-
dependent THALASSemiA patients) is the first randomized,
double-blind, placebo-controlled trial to assess deferasirox
(Novartis Pharmaceuticals, East Hanover, NJ, USA) for in-
vestigational use in patients with NTDT [9]. Results from the
1-year THALASSA study, the largest dataset to date in
NTDT patients, showed that liver iron concentration (LIC)
significantly decreased versus placebo [least-squares mean
(LSM)±standard error]: –2.33±0.7 (p=0.001) and −4.18±
0.69 mg Fe/g dry weight (dw) (p<0.001) for deferasirox
starting doses of 5 and 10 mg/kg/day, respectively [9]. LIC
increased by 0.38 mg Fe/g dw in patients receiving placebo
[9]. Patients treated with deferasirox had a similar frequency
of overall adverse events (AEs) as patients treated with
placebo [9].
In order to provide longer-term deferasirox data in NTDT
patients and to assess whether a greater number of patients
could reach the therapeutic goal of LIC <5 and <3 mg Fe/g
dw than observed in the core study, a 1-year extension phase
was carried out. This allowed assessment of up to 2 years of
deferasirox treatment, the longest assessment of chelation in
a controlled trial in NTDT patients, and the opportunity for
patients treated with placebo in the core to receive defera-
sirox in the extension phase, as well as to provide further
guidance on dosing and monitoring strategies.
Methods
Study design
THALASSA is a multinational, prospective, randomized,
double-blind, placebo-controlled phase II study (27 centers
across nine countries). Study design/inclusion/exclusion cri-
teria have been described previously [9].
Patients randomized to deferasirox during the core (start-
ing dose 5 or 10 mg/kg/day) and those receiving placebo had
the option to enter a pre-planned, 1-year, open-label exten-
sion phase. Written, informed consent was required prior to
extension entry. Patients with continuous increases in serum
creatinine ≥33 % above baseline and above the upper limit of
normal (ULN), alanine aminotransferase (ALT) >2× baseline
and >5× ULN, or progressive proteinuria that did not im-
prove after drug interruption/dose reduction in the core were
excluded from entering the extension.
Deferasirox starting doses in the extension were based on
LIC at the end of core and response to chelation (Fig. 1).
Extension dosing therefore differed from the core; patients
could start the extension receiving 20 mg/kg/day whereas in
the core starting doses were randomly assigned as 5 or 10-
mg/kg/day. After 6 months in the extension, dose adjust-
ments were made based on LIC measurement [9]. Dose
adjustment recommendations were also provided based on
continuous safety assessments. Treatment was to be inter-
rupted in patients reaching LIC <3 mg Fe/g dw or serum
ferritin <100 ng/mL.
The study was conducted in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki. The study
Patients with LIC
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LIC <3 Interrupt*
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Fig. 1 Starting doses in the THALASSA extension study. *Wait until
LIC >5 mg Fe/g dw and then restart at 5 mg/kg/day if 5 mg/kg/day was
effective before interruption or at 10 mg/kg/day if 10–20 mg/kg/day
was effective before interruption
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was approved by local ethics committees of study sites. An
independent data monitoring committee reviewed safety data
and advised on study continuation and/or protocol changes.
Assessments
The primary efficacy endpoint for the extension was the
number and proportion of patients reaching LIC <5 mg
Fe/g dw by the end of the extension. Additional analyses
included assessment of the number and proportion of
patients with LIC <3 mg Fe/g dw and the change in serum
ferritin. LIC was measured at baseline then every 6 months
using a validated R2MRI technique (FerriScan®; Resonance
Health, Perth, Australia) [12].
Secondary endpoints included correlation of serum ferri-
tin with LIC and change in LIC and serum ferritin in patients
who interrupted therapy as a result of LIC <3 mg Fe/g dw or
serum ferritin <100 ng/mL.
Serum ferritin was measured at baseline then monthly or
quarterly (depending on whether the patient was still receiv-
ing deferasirox). Mean iron excretion was calculated by
adapting the Angelucci formula [13]: mean iron excretion
(mg/kg/day)=10.6×(change in LIC)/days (730).
Safety was evaluated through continuous monitoring and
recording of AEs, laboratory testing, and clinical evaluations.
For patients with LIC <5 mg Fe/g dw or serum ferritin
≤300 ng/mL, AE incidence before and after the first day of
the event was summarized and adjusted for exposure duration.
Statistical methods
Statistical analyses for the core have been reported previously
[9]. For the primary efficacy analysis, the proportion of patients
who reached LIC <5 mg Fe/g dw by the end of the extension is
presented with a 95% confidence interval (Wilson CI) [14]. For
data analyses presented by average actual dose, patients were
summarized by the dose category regardless of their treatment
groups. Descriptive statistics were used to present efficacy
analyses. Compliance was reported as planned dose taken=
100×cumulative dose taken/cumulative planned dose.
Data were assessed by various groupings (core+extension
and extension only) and core randomization arms. Primary
analysis set for efficacy is the core+extension full analysis set
(FAS) consisting of randomized patients in the core. Analyses
for the core+extension FAS summarized data cumulatively
from core randomization date. The extension FAS is random-
ized patients who entered the extension.
The core+extension safety set consists of all randomized
patients who received ≥1 study drug dose. Analyses summa-
rized all safety data cumulatively from the start date of the
first dose in the core. Extension safety set was all randomized
patients who entered the extension and received ≥1 defer-
asirox dose during the extension.
When reporting events by starting dose in the extension
only, if the first actual deferasirox dose in the extension was
<15 mg/kg/day, the patient was analyzed in the combined
≤10 mg/kg/day group; if the first actual dose in the exten-
sion was ≥15 mg/kg/day, the patient was analyzed in the
20 mg/kg/day group.
The study was sponsored by Novartis Pharma AG and
designed by the sponsor in collaboration with the Study Steer-
ing Committee composed of expert hematologists in the thal-
assemia field. The sponsor conducted the statistical analysis.
Authors had full access to data and actively participated in
data interpretation and drafting/critical manuscript review,
with the assistance of a medical writer funded by the sponsor.
The corresponding author had final responsibility for manu-
script content and decision to submit for publication.
Results
Patient disposition and baseline demographics
Overall, 148 patients completed the core (97 and 51 in the
deferasirox and placebo arm, respectively) [9], of whom 15
did not enroll in the extension (Fig. 2). Of the 133 patients
entering into the extension, 130 completed.
Blood transfusions and exposure to treatment
For patients receiving deferasirox in the core and extension
(n=110), 88 (80.0 %) did not receive blood transfusions
during the study. Twelve (10.9 %), five (4.5 %), two
(1.8 %), one (0.9 %), and two (1.8 %) patients received 1,
2, 3, 4, or >4 transfusions, respectively.
Patients receiving deferasirox in the core and extension
were treated for a median duration of 23.3 months (range
0.2–27.1). In the extension year, the median duration of defer-
asirox was 11.1 months (range 1.1–12.2). Taking into consid-
eration dose adjustments and the fact that patients entering the
extension could begin at a 20mg/kg/day starting dose whereas
in the core starting doses were 5 or 10 mg/kg/day, the mean
actual deferasirox dose in the deferasirox core+extension
group was 9.8±3.6 (median 9.5) mg/kg/day. In the deferasirox
extension group, the mean actual deferasirox dose was 12.6±
4.5 (median 10.8) mg/kg/day, and for patients in the crossover
extension group it was higher at 13.7±4.6 (median 14.0)
mg/kg/day (Table 1).
For patients entering the extension phase, in the defera-
sirox extension group, 64 (78.0 %) patients were in the
≤10 mg/kg/day group and 18 (22.0 %) patients were in the
20 mg/kg/day group. In the crossover group, 27 (56.3 %)
were in the ≤10 mg/kg/day and 21 (43.8 %) were in the
20 mg/kg/day groups.
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Average actual dose by dose category is shown in Table 1.
In the deferasirox extension group, average actual dose
breakdown was similar to those who were switching from
placebo to deferasirox. Medication compliance was high in
the extension phase with 97.2±7.0 % in the deferasirox
extension group and 96.0±8.1 % in the crossover extension
group taking the planned dose.
In the extension phase, doses were decreased as a result of
AEs in 19 (23.2 %) patients in the deferasirox extension
group [main reason gastroenteritis (six patients)] and 18
(37.5 %) patients in the crossover extension group [main
reason gastroenteritis (four patients)].
Effect of deferasirox on LIC and serum ferritin
Following the LIC decrease over 1 year with deferasirox,
mean LIC continued to decrease over another year (Fig. 3).
Baseline LIC [± standard deviation (SD)] in the deferasirox
core+extension group (n=110) was 13.84±7.61 mg Fe/g dw;
at month 24, LIC had decreased to 7.51±6.21 mg Fe/g dw
(mean absolute change −7.14±5.3 mg Fe/g dw). For the
placebo/deferasirox group (n=56), baseline LIC was 15.94±
10.85mg Fe/g dw; at 1 year with placebo, mean LIC increased
to 16.38±10.43 mg Fe/g dw. Following the crossover to
deferasirox in the extension phase, mean LIC decreased to
10.28±8.80 mg Fe/g dw at month 24 (mean absolute change
baseline to month 24 = –6.66±6.63 mg Fe/g dw).
In the deferasirox core+extension group, absolute change
in LIC by average actual dose category showed a dose
response, with the highest decreases seen in the higher dose
groups. Mean±SD change in LIC from baseline to month 24
was −4.4±4.60, –6.6±3.99, –10.0±5.86, and −10.4±11.53
in the >0 to <7.5 (n=15), 7.5–12.5 (n=47), >12.5–17.5 (n=
18), and >17.5 (n=4) mg/kg/day groups, respectively.
At 24 months, the largest absolute decrease in LIC was seen
in patients with the higher baseline LIC. Patients in the defer-
asirox core+extension group with a baseline LIC of ≤7 (n=18),
>7–15 (n=57), and >15 mg Fe/g dw (n=35) had a mean±SD
LIC reduction of −2.5±1.16 (n=10), –5.4±2.66 (n=45), and
−11.4±6.31 mg Fe/g dw (n=29), respectively. The overall
mean net iron excretion was 0.104 mg/kg/day; in patients with
baseline LIC ≤7, 7–15, and >15 mg Fe/g dw, the mean iron
excretion was 0.036, 0.078, and 0.166 mg/kg/day, respectively.
The percentage of patients achieving LIC <5 and <3 mg
Fe/g dw continued to increase over 2 years. Of 166 patients
enrolled, 29 (17.5 %) patients achieved LIC <5 mg Fe/g dw
by the end of the core [15 (9.0 %) patients in the deferasirox
10 mg/kg/day group, nine (5.4 %) in the deferasirox
5 mg/kg/day group, and five (3.0 %) in the placebo group
(apparent improvement in the placebo group attributable to
MRI variability)] [9, 12]. By the end of the extension, the
number of patients who had achieved LIC <5 mg Fe/g dw
Table 1 Average actual dose




Dose categories (mg/kg/day), n (%)
>0–≤7.5 7.5–12.5 >12.5–17.5 >17.5
Deferasirox core+
extension (n=110)
9.8±3.6 9.5 32 (29.1) 53 (48.2) 21 (19.1) 4 (3.6)
Deferasirox extension
(n=82)
12.6±4.5 10.8 6 (7.3) 40 (48.8) 19 (23.2) 17 (20.7)
Crossover extension
(n=48)
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Fig. 2 Patient disposition (groups reported in manuscript shaded in
gray)
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had increased to 64 [38.6 %; 43/110 (39.1 %; 95 % CI 30.5,
48.4) patients in the deferasirox core+extension group and
21/56 (37.5 %; 95 % CI 26.0, 50.6) patients in the placebo/
deferasirox group]. Overall, six (3.6 %) patients achieved
LIC <3 mg Fe/g dw by the end of the core study; this
increased to 24 (14.5 %) by the end of the extension.
Twenty-four patients in the core+extension who stopped
deferasirox as a result of achieving LIC <3 mg Fe/g dw or
serum ferritin <100 ng/mL had a mean LIC at the time of
stopping of 2.20±0.49 mg Fe/g dw. These patients were
followed up over an average duration of 257.8 days (range
162–362), and the last available LIC was 3.08±1.74 mg Fe/g
dw (n=13), with an absolute change after stopping of +0.87±
1.36 (range −1.4–4.5).
It is important to note that patients receiving placebo in
the core and then deferasirox in the extension entered the
extension with a higher extension baseline LIC (16.3 vs.
11.0 mg Fe/g dw) and received a higher average actual
deferasirox dose than those continuing on deferasirox
(Table 1). In the extension phase, patients with higher exten-
sion baseline LIC and in the higher dose categories achieved
the greatest reduction in LIC (Fig. 4).
Following the serum ferritin decrease over 1 year with
deferasirox (median decrease −163.3 ng/mL), serum ferritin
continued to decrease over another year (median decrease
−472.0 ng/mL from baseline to month 24) in the deferasirox
core and extension group (Fig. 5). Serum ferritin also de-
creased in the group switching from placebo to deferasirox in
the extension (median decrease −310.8 ng/mL from baseline
to month 24). For patients with extension baseline serum
ferritin >300 ng/mL (n=128), 18 (14.1 %) achieved serum
ferritin <300 ng/mL at the end of the extension.
Safety profile and laboratory parameters
Overall, the safety profile of deferasirox up to 2 years was
consistent with that seen in the core study [9]. Over the 2 years,
investigator-assessed drug-related AEs were reported in 35
(31.8 %) patients; most common (>5 %) were diarrhea, nau-
sea, and rash [all seven (6.4 %)].
For patients treated with deferasirox for up to 2 years, the




















6 12 18 24
55 47 46 41 40
55 47 47 41 44






















Deferasirox core starting dose 5 mg/kg/day
Deferasirox core starting dose 10 mg/kg/day
Placebo/deferasirox
Time (months)





















































































Extension BL 18 24





















































Fig. 4 aMean±SD absolute change in LIC by extension baseline LIC
categories from extension baseline to month 24. b Mean±SD absolute
change in LIC by average actual dose categories from extension base-
line to month 24 (all patients n=133)
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study drug relationship, before and after the first measurement
of LIC <5 mg Fe/g dw or serum ferritin ≤300 ng/mL (n=43)
was 36 (83.7 %; exposure-adjusted 36/45.2 years=0.80/year)
and 24 (55.8 %; exposure-adjusted 24/28.8 years=0.83/year),
respectively.
Over the 2 years of treatment, there was a decreasing trend
in mean ALT (Fig. 6). Mean serum creatinine and creatinine
clearance measurements showed slight increasing and de-
creasing trends, respectively; urinary protein/creatinine ratio
after an initial increase remained stable over 2 years (Fig. 6).
In the extension phase, AEs regardless of study drug
relationship were reported in 69.5 % of patients in the defer-
asirox extension group (68.8 % and 72.2 % in the ≤10 and
20 mg/kg/day groups, respectively) and 81.3 % in the cross-
over group (85.2 % and 76.2 % in the ≤10 and 20 mg/kg/day
groups, respectively). The most common AEs (>10 %) re-
gardless of study drug relationship in all patients were upper
respiratory tract infection (17.7 %), diarrhea (14.6 %), py-
rexia (12.3 %), and upper abdominal pain (11.5 %).
In the extension phase, investigator-assessed deferasirox-
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Fig. 5 Median absolute change (±25th/75th percentiles) in serum fer-







































































































































































Fig. 6 Mean ALT, serum
creatinine, creatinine clearance,
and urinary protein/creatinine
ratio over 2 years.
Measurements in month 24
were defined as those with study
day greater than 30×24−15=
705. In all safety analyses, the
observations or measurements
after 28 days of the last
treatment would be excluded
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patients in the deferasirox extension and crossover extension
groups, respectively. The most common (≥3 patients) were
diarrhea, blood creatinine increase, and headache [all three
patients (3.7 %) in the deferasirox extension group; diarrhea,
four patients (8.3 %) in the crossover group; Table 2]. Seri-
ous AEs (SAEs) regardless of study drug relationship were
observed in 10 (12.2 %) patients in the deferasirox extension
group [most common gastroenteritis, five patients (6.1 %)]
and 10 (20.8 %) patients in the crossover extension group
[most common anemia, three patients (6.3 %)]. One SAE
(hepatitis) suspected to be drug-related was observed in the
crossover 20 mg/kg/day group, which lasted for 47 days
(grade—severity three). Deferasirox dose was temporarily
interrupted and the patient was hospitalized. The SAE resolved
and the patient was restarted on 5 mg/kg/day and completed
the extension phase. No deaths occurred in the study.
In the extension phase, one patient in the deferasirox
≤10 mg/kg/day extension group and one patient in the cross-
over 20 mg/kg/day extension group had an increase in ALT
>5× ULN and >2× baseline on two consecutive visits (abso-
lute values—106, 114 and 400, 298 U/L, respectively); both
had abnormal extension baseline ALT (>ULN to ≤5× ULN).
The crossover patient also had one aspartate aminotransfer-
ase (AST) value >5× ULN and >2× baseline (AST≤ULN at
baseline). Deferasirox was interrupted and then restarted in
both patients; the ALT and AST increases observed were
transient. One additional patient experienced one AST value
>5× ULN and >2× baseline in the deferasirox ≤10mg/kg/day
extension group (AST≤ULN at extension baseline). AST
levels returned to normal without dose amendment or inter-
ruption. Elevated transaminases were also reported as AEs in
the above patients.
Two patients (one patient in the deferasirox extension
group and one in the crossover group) had serum creatinine
increases >33% above baseline and above ULN (106μmol/L)
on ≥2 consecutive visits while taking 20 mg/kg/day defera-
sirox (absolute values—120 and 114 μmol/L in the defera-
sirox extension patient and 112–142 μmol/L in the crossover
patient). Both patients had normal serum creatinine at exten-
sion baseline. The deferasirox dose in the deferasirox exten-
sion group patient was reduced and the serum creatinine levels
normalized. Elevated creatinine was also reported as an AE in
this patient. In the patient in the crossover group, serum
creatinine started improving after drug interruption (last value
remained 114 μmol/L). This patient also developed creatinine
clearance <60 mL/min at ≥2 consecutive visits. Creatinine
clearance before crossing over to deferasirox was 69 mL/min
and then it fluctuated from 40 to 58 mL/min.
One patient in the deferasirox extension group had creat-
inine clearance <60 mL/min at ≥2 consecutive visits (abso-
lute values ranged from 54 to 59 mL/min) while taking
5 mg/kg/day. This patient had an extension baseline creati-
nine clearance <60 mL/min. The dose was not changed; at
the next assessments, creatinine clearance ranged from 52 to
60 mL/min.
One patient in the crossover extension group had urinary
protein/creatinine ratio >1.0 mg/mg at ≥2 consecutive values
(absolute values ranged from 2.41 to 4.01) while taking
20 mg/kg/day. This patient had an abnormal urinary protein/
creatinine ratio of >0.2 to ≤1 mg/mg at both core and exten-
sion baseline. After drug interruption and deferasirox rein-
statement at 20 mg/kg/day, urinary protein/creatinine ratio
returned to baseline values at the end of the extension.
Mean±SD hemoglobin levels remained stable during the
extension phase (all patients: extension baseline—78.2±
16.5 g/L, month 24—79.8±16.7 g/L).
Discussion
The THALASSA trial provides the largest dataset for iron
chelation in NTDT to date, confirming preliminary findings
of iron reduction in small studies/case reports [3–8, 10, 11,
15]. The 1-year study established a treatment paradigm for
iron-overloaded NTDT patients whereby chelation with
deferasirox can be initiated when LIC exceeds 5 mg Fe/g
Table 2 Investigator-assessed drug-related AEs (≥3 overall) by starting dose in the extension
AE Deferasirox (extension study) Crossover (extension study)
≤10 mg/kg/day (n=64) n (%) 20 mg/kg/day (n=18) n (%) ≤10 mg/kg/day (n=27) n (%) 20 mg/kg/day (n=21) n (%)
Diarrhea 2 (3.1) 1 (5.6) 3 (11.1) 1 (4.8)
Upper abdominal pain 2 (3.1) 0 (0.0) 2 (7.4) 0 (0.0)
Increased blood
creatinine
2 (3.1) 1 (5.6) 1 (3.7) 1 (4.8)
Headache 3 (4.7) 0 (0.0) 1 (3.7) 0 (0.0)
Nausea 1 (1.6) 0 (0.0) 1 (3.7) 0 (0.0)
Abdominal pain 2 (3.1) 0 (0.0) 1 (3.7) 0 (0.0)
Skin rash 0 (0.0) 0 (0.0) 1 (3.7) 1 (4.8)
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dw and continued with a treatment goal of reducing LIC
below a threshold associated with complications [2].
Following the randomized, placebo-controlled 1-year
trial, we report here results from a 1-year extension phase,
providing the longest assessment duration of any iron chela-
tor in NTDT patients in a controlled trial setting. From the
baseline LIC and serum ferritin reported [9], it is clear that
despite no/limited transfusions, these patients have high iron
burden, and this high burden has been associated with com-
plications such as bone disease, thromboembolism, endo-
crinopathy, pulmonary hypertension, cerebrovascular and
neuronal damage, liver fibrosis or cirrhosis, and increased
risk of hepatocellular carcinoma (for overview see [16]).
Patients receiving deferasirox for one additional year
after the core study continued to respond with a decrease in
LIC and serum ferritin over 2 years. Overall, for patients
receiving deferasirox for up to 2 years, approximately 40 %
and 16 % reached LIC <5 and <3 mg Fe/g dw, respectively,
with more patients reaching these targets during the second
year, indicating that with appropriate dosing and contin-
ued treatment deferasirox continues to effectively remove
iron.
Patients crossing over from placebo in the core to defer-
asirox in the extension also showed a considerable decrease
in LIC and serum ferritin. These patients entered the exten-
sion with a higher extension baseline LIC, and received a
higher actual average deferasirox dose during the extension,
than those who received deferasirox during the core and
continued with treatment in the extension. This has contrib-
uted to the large decrease in LIC seen in the crossover
patients. This highlights the importance of monitoring iron
burden and dose adjusting when necessary to achieve thera-
peutic goals.
The safety profile over 2 years of deferasirox treatment
did not differ from that observed in the core 1-year study.
The overall incidence of AEs and abnormal laboratory
parameters were comparable in the extension and core phase
[9]. The safety profile did not appear to differ in the ≤10 and
the 20 mg/kg/day dose groups in the extension phase. There
was a gradual decrease in mean ALT over time, potentially
indicating a decrease in iron-related hepatocellular injury. A
slight increase in serum creatinine, gradual over 2 years, was
observed as the average dose increased.
The number of patients with worsening or new AEs,
regardless of drug relationship, whose LIC was <5 mg Fe/g
dw or serum ferritin was ≤300 ng/mL did not appear to differ
overall from that prior to achieving these levels, indicating
that chelation to these levels may not adversely affect the
number of worsening or new AEs.
A recent study revealed that patients with LIC >7 and
>6 mg Fe/g dw, respectively, were more likely to have an
already established vascular or endocrine/bone morbidity
[2]. Such information confirms the need to establish
therapeutic LIC goals specific to NTDT, which are likely to
differ from those already established in transfusion-
dependent patients. New NTDT guidelines [18], information
on the link between LIC and comorbidities [2] as well as data
from large studies on chelation such as THALASSA allow
some recommendations to be considered. Data from THA-
LASSA suggest that deferasirox can be used to reduce iron
burden in patients with LIC >5 mg Fe/g dw. Patients achiev-
ing LIC <3 mg Fe/g dw may be able to interrupt chelation
therapy; it is important to reiterate that LIC assessment is the
preferred option in NTDT patients, although serum ferritin
can be used to guide initiation, monitoring, and interruption
of chelation therapy [17]. After patients reach the therapeutic
target, the recommendation is to monitor them with LIC
evaluation every 1–2 years if feasible, which will identify
any patients whose LIC is approaching values of >5 mg Fe/g
dw and hence would require reintroduction of iron chelation
[18].
THALASSA is the longest controlled trial of iron chelation
in NTDT; however, it will be of interest to observe patients
over the longer term. In particular, it will be of interest to
observe patients who interrupt their chelation because they
achieved their therapeutic goals and to then determine when
they need to be reintroduced to chelation therapy as their
burden increases as they age.
In conclusion, THALASSA data confirm that deferasirox,
with appropriate dosing, effectively reduces iron overload
over 2 years with a manageable safety profile providing robust
evidence to assist clinicians in managing iron overload in
patients with NTDT.
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